Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)
17 Janvier 2017 - 10:42PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
14D--9
SOLICITATION/RECOMMENDATION STATEMENT
UNDER
SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No.
)
DERMA
SCIENCES, INC.
(Name of Subject Company)
DERMA SCIENCES, INC.
(Name of Persons Filing Statement)
Common Stock, par value $.01 per share
(Title of Class of Securities)
249827205
(CUSIP Number of Class of Securities)
John E. Yetter
Derma Sciences, Inc.
214 Carnegie Center, Suite 300
Princeton, NJ 08540
(609) 514-4744
(Name, address and telephone numbers of
person authorized to receive notices
and communications on behalf of the persons filing statement)
Copies to:
Todd E. Mason, Esq.
Thompson Hine LLP
335 Madison Avenue
12th Floor
New York, New York 10017
(212) 344-5680
|
x
|
Check the box if the filing relates solely to preliminary
communications made before the commencement of a tender offer.
|
The information contained in the Current Report on Form 8-K
filed by Derma Sciences, Inc. on January 17, 2017, including all exhibits filed or furnished with such Form 8-K, is incorporated
herein by reference.
Derma Sciences, Inc. (NASDAQ:DSCI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Derma Sciences, Inc. (NASDAQ:DSCI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Derma Sciences, Inc. (NASDAQ): 0 recent articles
Plus d'articles sur Derma Sciences, Inc.